Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis.

article OA: bronze CC0 ⤵ 54 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-07

Intranasal buserelin effectively resolved endometriotic lesions in five of six women after six months, inducing anovulation and suppressing menstruation while relieving symptoms.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

An agonist analogue of luteinising hormone releasing hormone (buserelin) was successfully used to treat women with endometriosis. A dose of 200 micrograms administered intranasally thrice daily was found to be effective in five patients, in whom the endometriotic lesions resolved after six months' treatment. Failure occurred in a sixth patient, who received only 400 micrograms once daily. Anovulation was induced in all subjects together with suppression of menstruation after the first month of treatment. Symptoms of abdominal pain, dysmenorrhoea, and dyspareunia were relieved during treatment, and one previously infertile patient conceived within two months of stopping treatment. No side effects were reported with this dosage, and the results suggest a new form of treatment for patients with endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrheadyspareunia

MeSH descriptors

Buserelin Endometriosis Adult Buserelin Creatinine Creatinine Endometriosis Endometriosis Estrogens Estrogens Female Humans Menstruation Menstruation Nose Ovulation Ovulation Pregnanediol Pregnanediol

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (13)

Cited by (50)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:55.985569+00:00
License: CC0 · commercial use OK